Efficasy and safety of tolvaptan in patients undergoing peritoneal dialysis with heart failure despite the standard treatment with conventional

INTERVENTION: Tolvaptane combination group: furosemide at a dose of 120mg daily for 3 days given in combination with tolvaptan 15mg/day Conventional treatment group: furosemide at a dose of 120mg daily for 3 days CONDITION: Chronic Heart Failure, Chronic Renal Failure PRIMARY OUTCOME: Change of Body Weight SECONDARY OUTCOME: urine volume, urine osmolarity, serum osmolarity, serum electrolyte concentration, hANP, BNP, fluid retention, water intake, NYHA functional classification, serum ADH, creatinine clearance, urine electrolyte concentration, total removed fluid with PD INCLUSION CRITERIA: 1)The patients with chronic heart failure 2)The patients undergoing peritoneal dialysis 3)The admitted patients 4)Male and Female 5)The patients over 20 years old in a time of consent 6)The patients with individual or representitive consent